摘要
目的探讨冠状动脉内推注硝普钠防治慢血流或无复流的有效性。方法通过PubMed、EMbase、Cochrane Library等数据库收集2018年3月之前公开发表的冠状动脉内使用硝普钠防治无复流的相关研究文献。应用Meta分析对所收集的文献进行综合定量评价,运用REVMAN 5.3进行统计学分析。结果共纳入文献7篇,累计硝普钠组443例,对照组411例。Meta分析结果显示,与对照组比较,硝普钠组能改善急性心肌梗死患者经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗后靶血管校正的心肌梗死溶栓试验(thrombolysis in myocardial infarction,TIMI)帧数(corrected TIMI frame count,CTFC);未能增加PCI治疗后ST段回落发生率、未能减少PCI治疗后主要不良心血管事件的发生。结论冠状动脉内推注硝普钠可以改善急性心肌梗死患者靶血管CTFC,未能改善PCI治疗后ST段回落及主要不良心血管事件的发生。
Objectives To evaluate the clinical efficacy of intracoronary nitroprusside for preventing no-reflow or slowflow in patients with acute myocardial infarction.Methods We searched PubMed,EMBase,Cochrane Library data⁃base to collect the relevant research literature about intracoronary nitroprusside in patients with acute myocardial in⁃farction which were published before March 2018.Meta-analysis was used to comprehensively and quantitatively evalu⁃ate the literature collected.REVMAN 5.3 was use to carry out statistical analysis.Results A total of 7 literatures were collected,involving 443 cases in nitroprusside group and 411 cases in control group.The results of the Meta analyses showed that intracoronary nitroprusside reduced the target vessel corrected thrombolysis in myocardial infarction(TI⁃MI)frame count(CTFC)in patients with acute myocardial infarction after percutaneous coronary intervention(PCI),while not increased ST-segment reduction and reduced major adverse cardiovascular event(MACE)occurrance.Conclusions Intracoronary nitroprusside can reduce CTFC,but not improve ST-segment reduction and not reduce the incidence of MACE in patients with acute myocardial infarction after PCI.
作者
曹斌
潘兰萍
蒋柏枫
邓振兴
陈玉红
CAO Bin;PAN Lan-ping;JIANG Bai-feng;DENG Zhen-xing;CHEN Yu-hong(Department of Cardiology,Yongzhou Central Hospital North Hospital,Yongzhou,Hunan 425000,China)
出处
《岭南心血管病杂志》
2020年第1期16-18,34,共4页
South China Journal of Cardiovascular Diseases
关键词
心肌梗死
慢血流
无复流
硝普钠
META分析
myocardial infarction
slow-flow
noreflow
nitroprusside
Meta analysis
